Ann: Mesoblast Maintains Momentum with FDA, page-101

FYI, yesterdays announcement resulted in articles being published by media and investement firms all over the world.

Below is just a sample of the large number of articles on the web:

Word is definitely spreading!

AInvest

Mesoblast:A Compelling Buy Ahead of Pivotal FDA Decision and Commercial Surge

“Thecompany stands on the brink of two critical catalysts: the July FDA meeting todiscuss Ryoncil's label expansion to adult steroid-refractory acutegraft-versus-host disease (SR-aGvHD) patients and its rapidly scalingcommercial launch. With robust payor coverage, proven clinical efficacy in alife-threatening orphan indication, and a fortress-like patent portfolio, Mesoblast is positioned tounlock significant value—if investors look past the stock's currentundervaluation.”

**promotion blocked**

MesoblastGives Positive Update About Potential FDA Application For Heart FailureTherapy: Retail Sees ‘Inflection Point’

Capital Brief

Mesoblastrallies after FDA progress on treatments Revascor and Ryoncil

TipRanks

MesoblastAdvances FDA Approvals for Revascor® and Ryoncil

Kalkine Media

Kalkine:ASX 200 Biotech Firm Mesoblast Gains Momentum Following FDA Developments

Biospace

MesoblastMaintains Momentum With FDA on Accelerated Approval

Market Screener

MesoblastMaintains Momentum With FDA on Accelerated Approval Pathway

GuruFocus

MesoblastLtd (MESO) Advances FDA Discussions for Key Therapies

Financial Analyst Perspective

From afinancial standpoint, Mesoblast's progress with the FDA is a positive indicatorof potential revenue growth. The successful commercial launch of Ryoncil andits expanding insurance coverage could significantly boost sales

Aktien

MesoblastMaintains Momentum With FDA on Accelerated Approval Pathway for Revascor® inIschemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD